Dupixent®

1-800-LAW-FIRM is actively investigating claims involving Dupixent®, a medication manufactured by Sanofi and Regeneron Pharmaceuticals and prescribed for eczema (atopic dermatitis), asthma, and other conditions linked to type 2 inflammation.

Recent studies have connected Dupixent to an increased risk of cutaneous T-cell lymphoma (CTCL) — a rare and serious form of non-Hodgkin lymphoma that causes abnormal T-cells to grow in the skin.

Why Patients Are Filing Dupixent Lawsuits

Lawsuits allege that Dupixent may trigger or worsen CTCL, yet manufacturers failed to provide adequate warnings.

Because CTCL can mimic eczema symptoms, many patients may have continued treatment unaware they had cancer, delaying diagnosis and allowing the disease to progress.

Potential Compensation for Patients

Living with eczema or asthma is already costly. If Dupixent worsened your health, those medical expenses and the emotional toll can be overwhelming. You may be entitled to compensation for:

• Medical bills and ongoing treatment costs
• Pain, suffering, and emotional distress
• Damages related to Dupixent’s failure to alleviate your symptoms

Take Action Now

If you or a loved one developed cutaneous T-cell lymphoma after taking Dupixent, don’t wait. Speak with your doctor about your treatment options, and contact 1-800-LAW-FIRM for a free legal review.

Call 1-800-LAW-FIRM today or complete our secure online form to find out if you qualify for a Dupixent lawsuit.

Please enable JavaScript in your browser to complete this form.

First Name *

Last Name *

Phone *

Email *

Who is the free claim review for? *SelfSpouseChildParentOther

Which litigation are you interested in discussing? *Bard PowerPort® CatheterBioZorb® MarkerCooperSurgical IVF SolutionOzempic® & SemaglutideSuboxone®Depo-Provera®Dacthal®Oxbryta®Dupixent®

What Date & Time (EST) would you like to schedule your free claim review? *

Date

Time

Please provide us with any information regarding your potential claim *

Consent Acknowledgement *

• By checking this box, I acknowledge and consent that the email address & phone number I have provided may be used to contact me by 1-800-LAW-FIRM or their partner law firms (including autodialed, pre-recorded calls or text messages).

Submit

Dupixent Lawsuits – Link Between Dupixent and Lymphoma

Dupixent® (dupilumab) is an injectable medication prescribed for eczema (atopic dermatitis), asthma, and other conditions tied to type 2 inflammation. While more than 1 million patients worldwide (including about 250,000 in the U.S.) use Dupixent, recent medical studies and patient reports suggest a potential increased risk of cutaneous T-cell lymphoma (CTCL) — a rare and serious form of non-Hodgkin lymphoma that affects the skin.

Why Are Dupixent Lawsuits Being Filed?

Dupixent lawsuits allege that the drug:

• Increases the risk of cutaneous T-cell lymphoma (CTCL)
• May accelerate undiagnosed lymphoma or worsen existing lymphoma
• Was marketed without adequate warnings about these cancer risks

Because CTCL often resembles eczema, many patients may have continued Dupixent treatments, delaying cancer diagnosis and allowing the disease to progress.

Medical Research on Dupixent and Lymphoma

• 2017: FDA approved Dupixent for eczema. Since then, dozens of CTCL cases have been reported.
• 2020 & 2021 studies: Found that Dupixent can worsen CTCL symptoms in patients already affected.
• 2024 Journal of the American Academy of Dermatology study: Showed increased risk of CTCL in Dupixent patients.
• Dermatologic Therapy: Reports show patients with eczema taking Dupixent have a 4.59× higher risk of CTCL compared to non-users.

Types of CTCL linked to Dupixent include:

• Mycosis Fungoides – most common type, causes rashes or raised skin bumps
• Sézary Syndrome – rarer, aggressive form that impacts skin and blood
• Other subtypes include Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Lymphoma, and more

Who Manufactures Dupixent?

Dupixent is jointly developed and marketed by Sanofi and Regeneron Pharmaceuticals, Inc. The companies continue to test Dupixent for additional uses despite growing safety concerns.

Who May Qualify for a Dupixent Lawsuit?

You may be eligible to file a claim if you or a loved one:

• Took Dupixent for at least one month to treat eczema, asthma, or another condition
• Were later diagnosed with cutaneous T-cell lymphoma (CTCL) or one of its subtypes, including Mycosis Fungoides, Sézary Syndrome, or other T-cell lymphomas
• Lost a family member due to complications associated with Dupixent

Possible Compensation

Compensation in a Dupixent lawsuit may include:

• Medical bills and treatment expenses
• Compensation for delayed or failed treatment outcomes
• Damages for pain, suffering, and long-term health complications
• Wrongful death benefits for surviving family members

Take Action – Dupixent Lawsuit Evaluation

If you or someone you love developed cutaneous T-cell lymphoma after taking Dupixent, you may have the right to pursue financial compensation. Our legal team is reviewing Dupixent claims nationwide.

Contact us today for a free, confidential case evaluation.

In addition to Dupixent, 1-800-LAW-FIRM is investigating Oxbryta lawsuits and Bard PowerPort claims.  Learn more about our dangerous drug litigation experience.